Unicycive Therapeutics Announced Results From The Oxylanthanum Carbonate UNI-OLC-201 Pivotal Trial, Established Favorable Tolerability And Safety And New Drug Application Submission Anticipated In Q3 2024
Unicycive Therapeutics Announced Results From The Oxylanthanum Carbonate UNI-OLC-201 Pivotal Trial, Established Favorable Tolerability And Safety And New Drug Application Submission Anticipated In Q3 2024
Unicycive Therapeutics宣佈來自氧蘭素碳酸鹽UNI-OLC-201關鍵試驗的結果，證實其良好的耐受性和安全性，新藥申請預計將在2024年第三季度提交。
Unicycive Therapeutics Announced Results From The Oxylanthanum Carbonate UNI-OLC-201 Pivotal Trial, Established Favorable Tolerability And Safety And New Drug Application Submission Anticipated In Q3 2024
Unicycive Therapeutics宣佈來自氧蘭素碳酸鹽UNI-OLC-201關鍵試驗的結果，證實其良好的耐受性和安全性，新藥申請預計將在2024年第三季度提交。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。